What is Merck & Company's stock symbol?
Merck & Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."
How often does Merck & Company pay dividends? What is the dividend yield for Merck & Company?
Merck & Company declared a quarterly dividend on Tuesday, November 22nd. Stockholders of record on Thursday, December 15th will be paid a dividend of $0.47 per share on Monday, January 9th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.87%. The ex-dividend date is Tuesday, December 13th. This is a positive change from Merck & Company's previous quarterly dividend of $0.46.
Where is Merck & Company's stock going? Where will Merck & Company's stock price be in 2017?
18 equities research analysts have issued 12-month price objectives for Merck & Company's stock. Their predictions range from $48.00 to $80.00. On average, they expect Merck & Company's stock price to reach $67.40 in the next twelve months.
When will Merck & Company announce their earnings?
Merck & Company is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.
What are analysts saying about Merck & Company stock?
Here are some recent quotes from research analysts about Merck & Company stock:
- BMO Capital Markets analysts commented, "Although expectations for EPOCH were low, we were looking for an efficacy signal in mild patients, which would have increased expectations for the APECS study. Merck's press release does not provide details regarding subgroup analysis in mild patients; however, the language suggests little to no efficacy. This lowers our probability of success for APECS from 50% to 25%, Verubecestat risk-adjusted sales from ~$5Bn in 2026 to ~$2.5Bn, and our valuation from $72 to $70. However, investors should not give up on Verubecestat; APECS has a higher chance of success." (2/15/2017)
Jefferies Group LLC analysts commented, "Our Underperform rating is predicated on under-appreciated margin pressure in the base business as well as over-optimistic expectations for Keytruda." (1/12/2017)
According to Zacks Investment Research, "We are positive on the company’s efforts to expand its pipeline and focus on core areas of expertise. Merck has made significant progress with its pipeline and is working on bringing new products to the market. New products, especially Keytruda should contribute meaningfully to the top line. The latest FDA approval of Keytruda for the first line treatment of metastatic lung cancer should sharply improve the drug’s sales. Merck will continue to focus on cost-cutting initiatives to drive the bottom line. The company has also been pursuing acquisitions and business development deals to boost its pipeline. Merck’s shares surpassed that of large-cap pharma industry this year. However, increased competition as well as generic challenges will continue to pressurize the top line. Nasonex and Cubicin lost patent exclusivity in 2016 which is hurting sales." (12/7/2016)
Who owns Merck & Company stock?
Merck & Company's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (1.04%), Barrow Hanley Mewhinney & Strauss LLC (0.64%), FMR LLC (0.49%), Federated Investors Inc. PA (0.41%), Dimensional Fund Advisors LP (0.24%) and AQR Capital Management LLC (0.24%). Company insiders that own Merck & Company stock include Adam H Schechter, Adele D Ambrose, Bruce N Kuhlik, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Peter C Wendell, Rochelle B Lazarus, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks.
Who sold Merck & Company stock? Who is selling Merck & Company stock?
Merck & Company's stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Highland Capital Management LP, Barrow Hanley Mewhinney & Strauss LLC, Tudor Investment Corp Et Al, NN Investment Partners Holdings N.V., Thornburg Investment Management Inc., Menora Mivtachim Holdings LTD. and Cadinha & Co. LLC. Company insiders that have sold Merck & Company stock in the last year include Adam H Schechter, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks.
Who bought Merck & Company stock? Who is buying Merck & Company stock?
Merck & Company's stock was acquired by a variety of institutional investors in the last quarter, including Asset Management One Co. Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Russell Investments Group Ltd., AQR Capital Management LLC, Coho Partners Ltd., Congress Asset Management Co. MA, Radnor Capital Management LLC and Orbimed Advisors LLC.
How do I buy Merck & Company stock?
Shares of Merck & Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Merck & Company stock cost?
One share of Merck & Company stock can currently be purchased for approximately $65.48.